查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1848739

癌症切片檢查市場（按產品類型、應用、技術和最終用戶）—2025-2032 年全球預測

Cancer Biopsy Market by Product Type, Application, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年癌症切片檢查市場規模將成長至 867.2 億美元，複合年成長率為 12.63%。

主要市場統計數據
基準年2024年 334.8億美元
預計2025年 377.6億美元
預測年份：2032年 867.2億美元
複合年成長率（%） 12.63%

策略性地建構臨床需求、設備創新和護理服務重新配置如何共同塑造跨護理環境的當代切片檢查實踐

本介紹將現代切片檢查實踐置於臨床需求、技術創新和不斷發展的醫療服務模式的交匯點。影像、設備和操作指南的進步正在重塑診斷工作流程，而人們對準確性、病患舒適度和周轉時間的期望不斷提高，也提升了微創取樣技術的作用。因此，多學科團隊正在重新調整通訊協定，以整合診斷準確性、通量和成本，而管理人員則優先考慮與更廣泛的基於價值的醫療目標相符的模式。

隨著相關人員面臨勞動力限制、監管審查和付款方動態變化，對有關程序選擇、技術採用和治療部位最佳化的強力證據的需求日益加劇。本執行摘要概述了影響實踐模式、供應鏈和供應商策略的關鍵趨勢，旨在為讀者提供清晰的方向，幫助他們了解在不同臨床環境中重新定義組織採集選擇、執行和管理方式的潛在力量。

關鍵的轉型變化凸顯了診斷影像的進步、向門診護理的轉變以及跨學科工作流程如何重新定義切片檢查實踐

由於技術的日趨成熟、工作流程的重新設計以及對以患者為中心的治療結果的日益重視，癌症切片檢查領域正在發生重大變化。影像導引方法日益複雜，能夠更精準地定位病灶，並減少非診斷性取樣。同時，隨著臨床醫生和管理人員力求降低成本、提高診療效率並改善患者體驗，手術路徑正從住院機構轉向門診手術和診斷影像中心。

同時，診斷方法正在融合，病理學家、放射科醫生和介入科醫生之間的合作更加緊密，組織採樣也得到最佳化，以用於下游的分子和基因組檢測。這種多學科整合正在影響設備設計、檢體處理通訊協定和供應鏈安排。因此，製造商和醫療保健提供者必須調整其策略，以支援無縫的臨床協作、法規遵循和品質保證，同時兼顧患者偏好和醫療機構的效率要求。

2025 年關稅環境如何重塑癌症切片檢查設備和耗材的籌資策略、採購彈性和服務成本模型

2025年近期關稅措施的累積影響將為依賴跨境供應鏈採購切片穿刺針、成像硬體、耗材和輔助設備的採購團隊、製造商和臨床服務提供者帶來層層複雜性。部分醫療設備和零件的進口關稅上調將推高到岸成本，獎勵企業重新評估籌資策略。這種環境將鼓勵採購領導者優先考慮供應商多元化、盡可能採用近岸外包，以及能夠在整個供應鏈中分配風險的合約結構。

在營運方面，醫院和診斷中心面臨嚴重的預算限制，可能會擴大庫存池和外包安排，以緩解價格波動。為此，醫療設備製造商正在探索重新設計以替代受關稅影響的零件，談判長期供應協議，並加快替代供應商的資格審查。法規合規性和品質保證仍然是不可協商的，任何採購轉變都必須保持臨床性能和無菌標準。最終，關稅環境促使人們重新評估成本服務模型，凸顯了建立透明的供應商關係和情境規劃以維持臨床連續性的必要性。

細分市場主導的洞察揭示了產品、應用、技術和最終用戶的差異如何推動臨床選擇、採購和創新重點

精細的細分視角能夠清楚地理解臨床需求、技術適用性和最終用戶能力之間的交集，從而確定採用模式和營運優先順序。按產品類型細分可以揭示諸如粗針穿刺切片和細針穿刺等替代方案之間的性能權衡，以及手術活體組織切片和真空輔助切片檢查在不同臨床場景中的相對作用。基於應用的細分可以揭示不同腫瘤部位的不同臨床切片檢查和檢體處理需求，包括乳房、肝臟、肺部、前列腺和甲狀腺手術的工作流程，這些都會影響設備的選擇和診斷影像需求。

我們對終端使用者的細分也揭示了門診手術中心、診斷影像中心、醫院和診所之間運作能力的差異。結合這些觀點，可以支援有針對性的產品開發、差異化的培訓項目以及商業性化方案，使設備功能與每個細分市場的臨床和營運實際情況相符。

區域動態和主要地區的醫療保健服務差異影響設備採用、監管策略和臨床工作流程最佳化

區域動態在塑造臨床通訊協定、報銷框架和設備可用性方面發揮著至關重要的作用，而這些因素又反過來影響採用曲線和供應商策略。美洲的醫療保健系統由私營和公共部門組成，構成複雜組合，高度重視成本控制和基於價值的治療結果，這使得醫療服務提供者青睞那些能夠提供可靠診斷結果和高效診療流程的診療程序。該地區的監管途徑和報銷政策也獎勵採用微創診療程序，以減少住院時間並加快診斷速度。

歐洲、中東和非洲是一個多元化的地區，每個國家的醫療保健系統和基礎設施水準都會影響技術的採用。資源豐富的市場正在迅速採用先進的影像引導和機器人輔助解決方案，而其他市場則優先考慮耐用、經濟高效的設備和本地培訓，以擴大覆蓋範圍。在亞太地區，快速的都市化、對腫瘤基礎設施的投資以及大量的手術量正在推動對擴充性解決方案和整合診斷路徑的需求。在所有地區，當地監管要求、供應鏈考量和勞動力技能將決定新切片檢查技術和服務模式的實際部署。

競爭性和策略性的公司評論重點關注設備整合、證據生成和夥伴關係主導的診斷途徑的創新

切片檢查系統的競爭態勢體現了技術差異化、戰略夥伴關係關係以及專注的臨床證據開發的融合。領先的公司優先投資於影像相容性、檢體儲存技術和整合流程平台，以簡化臨床工作流程並降低非診斷率。透過同儕審查研究和真實世界證據證明臨床結果改善的公司能夠贏得關鍵意見領袖和醫院採購委員會的信任，從而加速機構的採用。

同時，規模較小、專業化的參與企業正在透過滿足尚未滿足的程序需求來開拓利基市場，例如針對難以觸及的病變客製化的切片檢查設備，或針對分子級標本採集最佳化的工具。設備製造商與病理學和基因組學檢測提供者之間也正在形成策略聯盟，以最佳化從檢體採集到分子分析的整個診斷流程。最後，商業策略越來越受到服務模式的影響，包括培訓、程序支援和捆綁服務，這些模式有助於提供者以更低的營運摩擦採用新技術。

為製造商、醫療保健提供者和採購領導者提供實用的優先策略建議，以改善結果、降低供應風險並加速採用

設備製造、醫院系統和診斷服務的領導者可以採取具體措施來提升臨床療效、營運韌性和商業性績效。首先，投入資金，收集能夠證明診斷產量比率、治療決策和病人報告結果改善的證據。其次，制定靈活的供應結構和供應商多元化計劃，以減少單一來源中斷的風險，並透過尋找替代零件和近岸供應商來應對關稅主導的成本壓力。

第三，我們將整合介入放射學、病理學和腫瘤學團隊的回饋，根據每個臨床應用和最終用戶的細微需求客製化產品開發。第四，我們將建立策略夥伴關係，將組織採集與下游分子檢測結合，打造醫療系統重視的端到端解決方案。最後，我們將優先推動數位化，包括資料收集、工作流程整合和遠端監考，以提升品質保證，並促進不同醫療機構的規模化發展。

嚴格的多源調查方法結合了臨床醫生訪談、技術設備審查和證據三角測量，確保了可靠且可操作的見解

本研究採用三角調查方法，整合質性和量性證據，強調資料的完整性和可重複性。主要研究內容包括對臨床醫生、採購負責人和設備工程師的結構化訪談，以了解操作偏好、設備性能權衡和實施經驗。次要研究內容包括同行評審文獻、監管文件、操作指南和公開的技術規範，以檢驗臨床主張並為技術進步提供背景。

分析的嚴謹性透過跨資料流的方法學交叉驗證、關鍵假設的敏感性檢查以及臨床專家的迭代評審來實現，以確保解釋能夠反映現實世界的實踐。在某些情況下，案例研究和供應商提供的臨床數據也會進行方法學和偏差評估，並透明地記錄其局限性，以指導研究結果的合理應用。這種方法確保結論是實踐者見解、設備性能證據和監管環境的均衡綜合。

簡要概述策略要點和營運重點，以決定哪些切片檢查方法將被廣泛採用並獲得臨床信任。

結論綜合了分析中得出的關鍵主題：臨床需求、技術進步和操作限制共同推動著人們轉向更精準、侵入性更小且工作流程更便捷的活體組織切片解決方案。醫療保健決策者必須權衡流程有效性與營運考量，例如通量、切片檢查負擔和供應鏈穩定性。隨著診斷途徑與分子檢測日益融合，檢體完整性和標準化處理通訊協定將變得越來越重要。

展望未來，積極適應當地監管要求、建立策略夥伴關係關係並投資於證據生成的相關人員將最有能力影響臨床實踐並獲取價值。創新與實用化的相互作用將決定哪些技術將被廣泛採用，哪些技術仍將是利基解決方案，這凸顯了在商業、臨床和供應鏈職能部門中製定嚴謹的評估和適應策略的必要性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合液態生物檢體檢測，利用 ctDNA 和外泌體生物標記進行早期癌症檢測
  • 將人工智慧驅動的影像分析引入針刺活體組織切片程序可提高診斷準確性並縮短樣本處理時間
  • 開發一種能夠對深層腫瘤進行精確取樣的微創機器人切片檢查裝置
  • 擴展切片檢查標本中的次世代定序面板，以指導個人化腫瘤治療決策
  • 照護現場切片檢查平台，用於門診腫瘤科的快速分子分析
  • 結合循環性腫瘤細胞、DNA 和 RNA 的多檢體液態生物檢體測試的出現，可以實現全面的腫瘤表徵
  • 監管核准和報銷改革將加速關鍵市場創新切片檢查技術的商業化
  • 診斷公司和學術中心之間的合作，以檢驗新的切片檢查生物標記和通訊協定
  • 利用 cfDNA 甲基化分析進行多癌篩檢，泛癌早期檢測檢測的興起
  • 將人工智慧驅動的決策支援工具與切片檢查基因型數據相結合，以預測患者結果和治療反應

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章癌症切片檢查市場（按產品類型）

  • 芯針切片
  • 細針穿刺法
  • 手術切片檢查
  • 真空輔助切片檢查

第9章 癌症切片檢查市場（按應用）

  • 胸部
  • 肝
  • 肺
  • 攝護腺
  • 甲狀腺

第 10 章癌症切片檢查市場（按技術）

  • 影像引導切片檢查
  • 徒手手動切片檢查
  • 機器人輔助切片檢查

第 11 章 癌症切片檢查市場（按最終用戶）

  • 門診手術中心
  • 診斷影像中心
  • 醫院
  • 醫生辦公室

第 12 章癌症切片檢查市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 癌症切片檢查市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 癌症切片檢查市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Boston Scientific Corporation
    • Hologic, Inc.
    • Medtronic plc
    • Cardinal Health, Inc.
    • Cook Medical LLC
    • Becton, Dickinson and Company
    • Olympus Corporation
    • Argon Medical Devices, Inc.
    • Teleflex Incorporated
    • B. Braun Melsungen AG
Product Code: MRR-C27187914300

The Cancer Biopsy Market is projected to grow by USD 86.72 billion at a CAGR of 12.63% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 33.48 billion
Estimated Year [2025] USD 37.76 billion
Forecast Year [2032] USD 86.72 billion
CAGR (%) 12.63%

A strategic framing of how clinical needs, device innovation, and care delivery reconfiguration are jointly shaping modern cancer biopsy practice across care settings

The introduction positions contemporary cancer biopsy practice at the confluence of clinical imperative, technological innovation, and evolving care delivery models. Advances in imaging, instrumentation, and procedural guidance have reshaped diagnostic workflows, while heightened expectations for precision, patient comfort, and turnaround time have elevated the role of minimally invasive sampling techniques. Consequently, multidisciplinary teams are recalibrating protocols to integrate diagnostic accuracy with throughput and cost considerations, and administrators are prioritizing modalities that align with broader value-based care objectives.

As stakeholders confront workforce constraints, regulatory scrutiny, and shifting payer dynamics, the case for robust evidence on procedure choice, technology adoption, and site-of-care optimization grows stronger. Therefore, this executive summary frames the critical trends influencing practice patterns, supply chains, and vendor strategies, offering readers a clear orientation to the underlying forces redefining how tissue acquisition is selected, performed, and managed across diverse clinical settings.

Key transformative shifts revealing how imaging advances, care migration to ambulatory settings, and interdisciplinary workflows are redefining biopsy practice

The landscape of cancer biopsy is undergoing transformative shifts driven by technological maturation, workflow redesign, and a heightened emphasis on patient-centered outcomes. Imaging-guided approaches have become more sophisticated, enabling more precise targeting of lesions and reducing non-diagnostic sampling, while robotics and automation are beginning to emerge in select centers to improve reproducibility and safety. Meanwhile, procedural pathways are migrating from inpatient settings to ambulatory surgical centers and diagnostic imaging centers as clinicians and administrators seek to lower costs, improve throughput, and enhance patient experience.

In parallel, there is a convergence of diagnostic modalities, with pathologists, radiologists, and interventionalists collaborating more closely to ensure that tissue sampling is optimized for downstream molecular and genomic testing. This interdisciplinary integration is influencing device design, specimen handling protocols, and supply chain arrangements. As a result, manufacturers and providers must adapt their strategies to support seamless care coordination, regulatory compliance, and quality assurance, all while addressing patient preferences and institutional efficiency mandates.

How the 2025 tariff environment is reshaping sourcing strategies, procurement resilience, and cost-to-serve models for devices and consumables used in cancer biopsy

The cumulative impact of recent tariff actions in 2025 introduces a layer of complexity for procurement teams, manufacturers, and clinical providers that rely on cross-border supply chains for biopsy needles, imaging hardware, disposables, and accessory devices. Increased import duties on select medical devices and components amplify landed costs and create incentives for firms to reassess sourcing strategies. This environment encourages procurement leaders to prioritize supplier diversification, nearshoring where feasible, and contract structures that allocate risk across the supply chain.

Operationally, hospitals and diagnostic centers face tighter budgetary constraints and may extend inventory pooling and consignment arrangements to mitigate price volatility. In response, device makers are exploring redesigns that substitute tariff-exposed components, negotiating long-term supply agreements, and accelerating qualification of alternative suppliers. Regulatory compliance and quality assurance remain non-negotiable, so any sourcing pivot must preserve clinical performance and sterility standards. Ultimately, the tariff environment is prompting a re-evaluation of cost-to-serve models, while underscoring the need for transparent supplier relationships and scenario planning to maintain clinical continuity.

Segment-driven insights revealing how product, application, technology, and end-user differences drive clinical choice, procurement, and innovation priorities

A granular segmentation lens clarifies where clinical demand, technology fit, and end-user capabilities intersect to determine adoption patterns and operational priorities. Product Type distinctions illuminate performance trade-offs between alternatives such as Core Needle Biopsy versus Fine Needle Aspiration, and the relative roles of Surgical Biopsy and Vacuum-Assisted Biopsy in different clinical scenarios; these modalities differ in sample volume, diagnostic yield, and procedural setting requirements. Application-based segmentation highlights unique clinical pathways and specimen handling demands across tumor sites, including distinct workflows for Breast, Liver, Lung, Prostate, and Thyroid procedures that influence device selection and imaging needs.

Technology segmentation underscores the implications of Imaging Guided Biopsy compared with Manual Freehand Biopsy and the emerging role of Robotic Assisted Biopsy in enhancing precision and reproducibility, while end-user segmentation reveals how operational capabilities vary across Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, and Physicians Offices. When combined, these perspectives support targeted product development, differentiated training programs, and tailored commercial approaches that align device features with the clinical and operational realities of each segment.

Regional dynamics and care delivery variations across major geographies that influence device adoption, regulatory strategy, and clinical workflow optimization

Regional dynamics play a decisive role in shaping clinical protocols, reimbursement frameworks, and device availability, which in turn influence adoption curves and vendor strategies. In the Americas, healthcare systems span complex private and public mixes with strong emphasis on cost containment and value-based outcomes, prompting providers to favor procedures that deliver robust diagnostic yield with efficient throughput. Regulatory pathways and reimbursement policies in this region also incentivize adoption of minimally invasive techniques that reduce length of stay and expedite diagnosis.

Europe, Middle East & Africa present a heterogeneous landscape where national health systems and varying levels of infrastructure affect technology diffusion. In higher-resource markets, there is rapid uptake of advanced imaging-guided and robotic-assisted solutions, whereas other markets prioritize durable, cost-effective devices and local training to expand access. In Asia-Pacific, rapid urbanization, investments in oncology infrastructure, and high procedural volumes drive demand for scalable solutions and integrated diagnostic pathways. Across all regions, local regulatory requirements, supply chain considerations, and workforce skills shape the practical rollout of new biopsy technologies and service models.

Competitive and strategic company insights highlighting innovation in device integration, evidence generation, and partnership-driven diagnostic pathways

Competitive dynamics in the biopsy ecosystem reflect a blend of technological differentiation, strategic partnerships, and focused clinical evidence development. Leading firms are prioritizing investments in imaging compatibility, specimen preservation technologies, and integrated procedural platforms that streamline clinician workflows and reduce non-diagnostic rates. Companies that demonstrate clinical outcomes improvements through peer-reviewed studies and real-world evidence gain credibility with key opinion leaders and hospital procurement committees, thereby accelerating institutional adoption.

At the same time, smaller, specialized entrants are carving niches by addressing unmet procedural needs, such as biopsy devices tailored for difficult-to-access lesions or tools optimized for molecular-grade specimen collection. Strategic collaborations between device makers and pathology or genomic testing providers are emerging to ensure that the entire diagnostic pathway, from tissue acquisition to molecular analysis, is optimized. Finally, commercial strategy is increasingly informed by service models-training, procedural support, and bundled offerings-that help providers adopt new technologies with lower operational friction.

Practical and prioritized strategic recommendations for manufacturers, providers, and procurement leaders to improve outcomes, mitigate supply risk, and accelerate adoption

Leaders in device manufacturing, hospital systems, and diagnostic services can take concrete steps to strengthen clinical outcomes, operational resilience, and commercial performance. First, invest in evidence generation that demonstrates improvements in diagnostic yield, downstream treatment decision-making, and patient-reported outcomes; such data supports procurement discussions and clinician acceptance. Second, develop flexible supply arrangements and supplier diversification plans that reduce exposure to single-source disruptions and respond to tariff-driven cost pressures by qualifying alternative components and nearshore suppliers.

Third, align product development with the nuanced needs of each clinical application and end user by incorporating feedback from interventional radiology, pathology, and oncology teams; tailoring training and onboarding reduces implementation risk. Fourth, pursue strategic partnerships that integrate tissue acquisition with downstream molecular testing to create end-to-end solutions valued by health systems. Finally, prioritize digital enablement-data capture, workflow integration, and remote proctoring-to improve quality assurance and facilitate scale across disparate sites of care.

A rigorous, multi-source research methodology combining clinician interviews, device technical review, and evidence triangulation to ensure credible and actionable insights

The study synthesizes qualitative and quantitative evidence using a triangulated research approach that emphasizes data integrity and reproducibility. Primary inputs include structured interviews with clinicians, procurement leaders, and device engineers to capture procedural preferences, device performance trade-offs, and implementation experience. Secondary research encompasses peer-reviewed literature, regulatory filings, procedural guidelines, and publicly available technical specifications to validate clinical claims and contextualize technological advances.

Analytical rigor is achieved through methodical cross-validation across data streams, sensitivity checks on key assumptions, and iterative review by clinical experts to ensure that interpretations reflect frontline practice. Where applicable, case studies and vendor-provided clinical data are assessed for methodology and bias, and limitations are transparently documented to guide appropriate application of findings. This methodology ensures that conclusions rest on a balanced synthesis of practitioner insight, device performance evidence, and regulatory context.

A concise synthesis of strategic imperatives and operational priorities that will determine which biopsy approaches gain broad adoption and clinical trust

The conclusion synthesizes the dominant themes that emerged from the analysis: that clinical imperatives, technological evolution, and operational constraints are jointly driving a shift toward more precise, less invasive, and more workflow-friendly biopsy solutions. Institutional decision-makers must weigh procedural efficacy against operational considerations such as throughput, training burden, and supply chain stability. As diagnostic pathways become increasingly integrated with molecular testing, the importance of specimen integrity and standardized handling protocols will grow.

Looking ahead, stakeholders who proactively adapt to regional regulatory requirements, engage in strategic partnerships, and invest in evidence generation will be best positioned to influence clinical practice and capture value. The interplay between innovation and practical implementation will determine which technologies achieve broad adoption and which remain niche solutions, underscoring the need for disciplined evaluation and adaptive strategies across commercial, clinical, and supply chain functions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy assays for early cancer detection using ctDNA and exosomal biomarkers
  • 5.2. Adoption of AI-driven image analysis in needle biopsy procedures to enhance diagnostic accuracy and reduce sample processing times
  • 5.3. Development of minimally invasive robotic biopsy devices enabling precision sampling of deep-seated tumors
  • 5.4. Expansion of next-generation sequencing panels in biopsy specimens to guide personalized oncology treatment decisions
  • 5.5. Growth of point-of-care biopsy diagnostic platforms for rapid molecular profiling in outpatient oncology settings
  • 5.6. Emergence of multianalyte liquid biopsy tests combining circulating tumor cells, DNA, and RNA for comprehensive tumor characterization
  • 5.7. Regulatory approvals and reimbursement reforms driving commercialization of innovative biopsy technologies in major markets
  • 5.8. Collaborations between diagnostic companies and academic centers to validate novel biopsy biomarkers and protocols
  • 5.9. Rise of pan-cancer early detection assays leveraging cfDNA methylation profiling for multi-cancer screening
  • 5.10. Integration of AI-driven decision support tools with biopsy genotyping data to predict patient outcomes and therapy response

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biopsy Market, by Product Type

  • 8.1. Core Needle Biopsy
  • 8.2. Fine Needle Aspiration
  • 8.3. Surgical Biopsy
  • 8.4. Vacuum-Assisted Biopsy

9. Cancer Biopsy Market, by Application

  • 9.1. Breast
  • 9.2. Liver
  • 9.3. Lung
  • 9.4. Prostate
  • 9.5. Thyroid

10. Cancer Biopsy Market, by Technology

  • 10.1. Imaging Guided Biopsy
  • 10.2. Manual Freehand Biopsy
  • 10.3. Robotic Assisted Biopsy

11. Cancer Biopsy Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals
  • 11.4. Physicians Offices

12. Cancer Biopsy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Biopsy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Biopsy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Boston Scientific Corporation
    • 15.3.2. Hologic, Inc.
    • 15.3.3. Medtronic plc
    • 15.3.4. Cardinal Health, Inc.
    • 15.3.5. Cook Medical LLC
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. Olympus Corporation
    • 15.3.8. Argon Medical Devices, Inc.
    • 15.3.9. Teleflex Incorporated
    • 15.3.10. B. Braun Melsungen AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOPSY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GCC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GCC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GCC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. GCC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. GCC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. GCC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. GCC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. GCC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. GCC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. GCC CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. BRICS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. BRICS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. G7 CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. G7 CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. G7 CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. G7 CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. G7 CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. G7 CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. G7 CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. G7 CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. G7 CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. G7 CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NATO CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NATO CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NATO CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NATO CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NATO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. NATO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NATO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. NATO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. NATO CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. NATO CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED STATES CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED STATES CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. CANADA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. CANADA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. CANADA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. CANADA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. MEXICO CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MEXICO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. MEXICO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. MEXICO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. MEXICO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. MEXICO CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. MEXICO CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. BRAZIL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. BRAZIL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. BRAZIL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. BRAZIL CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. GERMANY CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. GERMANY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. GERMANY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. GERMANY CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. FRANCE CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. FRANCE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 306. FRANCE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 307. FRANCE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. FRANCE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. FRANCE CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. RUSSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. RUSSIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. RUSSIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. RUSSIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 316. RUSSIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 317. RUSSIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. RUSSIA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. ITALY CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. ITALY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. ITALY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. ITALY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. ITALY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. ITALY CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. ITALY CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. SPAIN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. SPAIN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. SPAIN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 330. SPAIN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 331. SPAIN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 332. SPAIN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 333. SPAIN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. SPAIN CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. CHINA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. CHINA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. CHINA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 338. CHINA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 339. CHINA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 340. CHINA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 341. CHINA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. CHINA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. INDIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. INDIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 345. INDIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 346. INDIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 347. INDIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 348. INDIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 349. INDIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 350. INDIA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 351. JAPAN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. JAPAN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 353. JAPAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 354. JAPAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 355. JAPAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 356. JAPAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 357. JAPAN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 358. JAPAN CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 359. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 360. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 361. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 362. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 363. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 364. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 365. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 366. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 367. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 201